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Introduction
Despite advances in diagnosis and staging, (neo-)
adjuvant therapy and surgical technique, the overall
survival of the esophageal carcinoma remains lower
than other solid tumors [1,2]. Esophageal cancer is
usually detected at an advanced stage, requiring a mul-
timodal concept. Numerous patients develop locally
recurrent tumors or distant metastases within a short
period of time after curative surgery. Despite the pres-
ence of tumour specific cytotoxic T cells and natural
killer cells, the immune system fails to contain
esophageal carcinomas [3,4]. As in other malignant
tumors, esophageal cancer cells actively suppress the
immune defence of the host by secreting a number of
immunosuppresive factors [5,6]. However, the mecha-
nisms by which such factors overcome anti-tumour
immunological responses are still poorly understood. 
Fas ligand (FasL), a type II membrane-bound 40-
kDa protein which belongs to the tumour necrosis fac-
tor (TNF) family, induces apoptotic death of sensitive
lymphoid cells expressing its cell surface receptor
(FasR) [7]. Activated T and B lymphocytes express
FasR, and thus are sensitive to FasR-mediated apopto-
sis [7,8]. This has been proposed to be responsible for
several regulatory functions of the immune system,
including tolerance acquisition, down-regulation of
immune reactions, and clonal deletion of peripheral
lymphocytes [3,9-11]. The expression of FasL has
been shown in colon carcinoma [12], gastric carcino-
ma [13], hepatocellular carcinoma [14], lung carcino-
ma [15], breast carcinoma [16], ovarian carcinoma
[17], esophageal carcinoma and their lymph node
metastases [18,19] that may trigger apoptosis of acti-
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vated lymphocytes. This process suggests that the
FasL allow tumors to escape the host's immune surveil-
lance [4]. However, the distribution of these molecules
does not correlate simply with the degree of malignan-
cy, and the biologic features of these molecules are not
fully understood. The membrane-bound FasL (mFasL)
may be cleaved by a specific matrix metalloproteinase-
like enzyme and be presented in a soluble form (sFasL).
Human sFasL is a 26-kDa glycoprotein consisting of an
extracellular region for binding to FasR and it has been
identified in the culture supernatant of FasL expressing
cells [20]. Membrane form of FasL as well as sFasL
binds to Fas and transduces an apoptotic signal in Fas-
expressing cells [21]. Elevated serum sFasL concentra-
tions have been observed in patients with various kinds
of hematological malignancies [20,22]. However, to our
knowledge there are few reports to date that demon-
strate elevated serum sFasL levels in patients with solid
tumours [12,23,24]. 
In the present study we measured the serum con-
centration of sFas-L in patients with esophageal carci-
noma and examined whether the results were correlat-
ed with clinicopathologic feature and survival rates.      
Materials and methods
Patients. One hundred esophageal cancer patients (89 men and 11
women, with a median age of  59.1 years, range from 34 to 81
years) diagnosed and treated at the Bialystok Medical University in
the Department of Thoracic Surgery were enrolled in this study.
The inclusion criteria were no previous history of malignancy, pri-
mary squamous cell carcinoma of the esophagus confirmed
histopathologically, no previous radiotherapy, chemotherapy,
immunotherapy and no anti-inflammatory drugs during the pre-
ceding 2 weeks. Patients with liver function failure such as viral
hepatitis, alcohol hepatitis, and fatty liver were excluded. Patients
who smoked at least 1 pack of cigarettes a day (smokers) and drank
at least 20g of ethanol daily for 5 or more years were assessed sep-
arately. We also studied 41 age-matched healthy subjects, all of
whom were infection free and none of whom had taken any drugs
in the 2 weeks preceding blood sampling. The clinicopathological
stage was determined according to the TNM classification system
of the International Union Against Cancer [25]. A relatively large
number of patients had advanced stage disease (71 patients, 71%).
Seventy-three patients (73%) had lymph node metastases, and 23
patients (23%) had distant metastases. The study population had
the following performance status (PS): PSO, 61 patients; PS1, 31
patients; and PS2, eight patients. Forty two patients underwent pri-
mary surgery and 58 received chemio- and/or radiotherapy. In
operated patients and patients treated with chemio- and/or radio-
therapy, mean follow-up duration was 18 months (range, 5-90) and
8 months (range, 3-24), respectively. The clinicopathological data
of all patients are shown in Table 1. Informed consent was obtained
from all healthy volunteers and all patients. 
Measurement of serum sFasL concentration. Venous blood sam-
ples were drawn into sterile vacuum tubes when esophageal carci-
noma was detected before surgery or anticancer therapy. The tubes
were centrifuged at 3000 rpm and separated sera were stored at -
80°C for future use.
The level of soluble Fas Ligand (sFasL) in the sera was deter-
mined with enzyme ligand immunosorbent assay (ELISA) kit for
the quantitative detection of human sFasL (Bender MedSystem,
Vienna, Austria) according the producer's protocol. Briefly, 50 μl
of a serum together with the same amount of Sample Diluent were
added to the corresponding sample well of the microwell plate.
After the sFasL present in the sample had bound to the anty-sFasL
coating antibodies adsorbed to the microwells, 50 μl of diluted
Biotin Conjugate solution was added. During the microplate incu-
bation at room temperature for 2 hours biotin-conjugated mono-
clonal anti-sFasL antibodies present in Biotin conjugate Solution
bound to sFasL captured by the first antibody. After the removal
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Table 1. Clinicopathological data of patients with primary
esophageal squamous cell carcinoma
unbound biotin-conjugated anti-sFasL during four washing steps,
each with approximately 300 μl of Wash Buffer, 100 μl of diluted
Streptavidin-HRP was added. Following incubation at room tem-
perature for 1 hour unbound Streptavidin-HRP was removed dur-
ing four washing steps with approximately 300 μl of Wash Buffer
each, and 100 μl of TMB Substrate Solution reactive with HRP
was added. After incubation at room temperature for 20 minutes
the reaction was stopped by adding 100 μl of Stop Solution (1 M
phosphoric acid), and the absorbance was measured at 450 nm with
a microplate reader (ETI System Sorin Biomedica).
sFasL sample concentration was determined on the base of a
standard curve prepared from seven sFasL standard dilutions. All
the sera samples were analyzed in duplicate, and the limit of detec-
tion was determined to be 0.1 ng/ml.
The patients were divided into two groups according to the
level of sFasL in the serum. A level of sFasL greater than the mean
level of sFasL plus 3 standard deviations in healthy controls was
regarded as a high level, and a level less than the mean level of
sFasL plus 3 standard deviations in healthy controls was regarded
as a low level. 
Statistical analysis. The U-Mann-Whitney test for two independ-
ent probes were used to analyze the correlation between serum
sFasL and patients parameters, including histopathologic findings.
The Kaplan-Meier method was used to generate survival curves.
Survival differences were analyzed with the log-rank test, based on
the status of level sFasL (high level and low level). Probability val-
ues <0.05 were considered statistically significant. All of the analy-
ses were performed using statistical analysis software (SPSS ver-
sion 13.0 for Windows).
Results  
Associations between sFasL serum levels and clinical
factors are shown in Table 2. The mean serum sFasL
levels in the healthy individuals and the squamous cell
esophageal cancer patients were significantly different
(0.261 ± 0.435 vs 1.567 ± 1.786; p<0.0001). The
serum levels of soluble FasL were not related to gen-
der (p=0.343), age (p=0.694) and tumor size
(p=0.649). No statistically significant correlation
between levels sFasL and T-stage was noted. No cor-
relation was found, either, between serum levels and
tobacco smoking (p=0.068) and history of chronic
alcohol intake (p=0.318).
Serum sFasL levels had a statistically significant
relationship to the N-stage (p<0.0389) and M-stage
(p<0.0388). The sFasL concentrations in stage IV were
significantly higher than they were in both the stage II
(p<0.034) and III (p<0.041). Statistically significant
difference was observed with respect to histopatholog-
ic grading. The sFasL concentration in well differenti-
ated tumors was significantly lower than in patients
with moderate differentiated (p<0.027).   
Kaplan-Meier survival curves for operated patients
and patients treated with chemio- and/or radiotherapy
categorized according to serum sFasL high level and
low level are shown on Fig. 1a and Fig. 1b. Survival of
patients with high level was not statistically different
to those with low level according to the long-rank test
in operated patients (p=0.525) and received oncologi-
cal treatment (p=0.840).  
Discussion
Recent studies indicating that most of the tumors
escape from the host immune attack by imitating them-
selves as immune-privileged sites by either overex-
pressing FasL or down-regulating Fas [4,12,13]. It has
emerged that esophageal cancers can also counterat-
tack the immune system. Expression of FasL by
esophageal carcinoma cells in vivo enables them to
induce Fas-mediated apoptosis of activated tumor-
infiltrating lymphocytes. This counterattack model
suggests that the FasL may offer a survival advantage
to tumors [6]. FasL proteins were detected in tumors
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Fig. 1. Kaplan-Meier survival curves demonstrate no statistical
difference: a. (p=0.525; long-rank test) between low level and
high level of sFasL esophageal cancer patients undergoing sur-
gery; b. (p=0.840; long-rank test) between low level and high
level of sFasL esophageal cancer patients undergoing chemio-
and/or rediotherapy.
tissues and their lymph node metastases in patients
with squamous cell esophageal cancer, and cell death
was detected in tumor infiltrating lymphocytes
[4,18,19]. The biologic significance of circulating
sFasL in esophageal cancer is currently unknown.
High levels of sFasL in serum have been generally
detected in several haematological diseases including
NK-cell leukaemia, NK cell lymphoma [20], but there
is little published data relating to patients with non-
hematopoietic malignancies [12,23,26,27], and none
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Table 2. Correlation between serum soluble Fas ligand (sFasL), healthy group and clinicopathologic data of patients with primary
esophageal squamous cell carcinoma
concerning the role of sFasL in esophageal carcinoma.
We investigated the role of serum sFasL concentration
in the biology of squamous  cell carcinoma. We
demonstrated that the level of serum sFasL in patients
with esophageal cancer was significantly higher than
in healthy volunteers, a finding that is in line with the
data reported by Lim [27], Hara et al. [28] and Mizu-
tani et al. [22] in different kinds of tumors. Further-
more, the serum levels of sFasL in stage III to IV
esophageal cancer patients were significantly higher
than they were in patients with stage II disease. These
results suggest that the increase in serum sFasL in
patients with squamous cell esophageal cancer might
be reflective of their tumor burden insofar as the tumor
may release sFasL.
Ohbu et al. [29] reported that the rate of apoptosis
was higher in well-differentiated esophageal tumors
than in poorly differentiated tumors. Our date demon-
strate that the level of serum sFasL in patients with well-
differentiated esophageal cancer was significantly lower
than in patients with moderate differentiated. Therefore,
it would be possible that the survival advantage seen in
low level serum sFasL cases is due to the occurrence of
frequent apoptosis in well differentiated esophageal
squamous cell cancers (data not shown).
The metastatic cascade is a complex series of
processes including angiogenesis, intravasation of
tumor cells, transport by circulation, adhesive interac-
tion with the endothelial cells, and extravasation. Our
results show circulating serum sFasL concentration are
significantly higher in patients with regional lymph
node metastases and/or distant metastases than in
patients without metastases. These findings suggest
that elevated levels of serum sFasL may induce the
apoptosis of activated lymphocytes and thus facilitate
tumor cell progression as a result of immunosurveil-
lance escape [30]. An evasion of the host immune sur-
veillance may be important for metastasis when cancer
cells enter into circulation. Our data supports the
hypothesis of others [4,6,19] who have recently pro-
posed a ''counterattack model'' suggesting that tumor
cells use FasL and sFasL as cytolytic effectors to kill
Fas-expressing activated lymphocytes, thus indicating
that both may offer subsequent tumor survival advan-
tage and regional lymph node and/or distant metastasis.
The precise cellular origins of sFasL have not been
elucidated. The present study has shown that high
serum levels of sFasL were mostly observed in
advanced stage of disease and moderate and poorly
differentiated tumors. We speculate that sFasL may be
derived from cancer cells which revealed high overex-
pression [31]. It has been reported that sFasL was
detected in culture supernatant of several cancer cells
[20,21,30].
High serum sFasL levels in esophageal cancer
patients may represent a further mechanism of
immune escape as a result of an attack against immune
cytotoxicity cells [23], but their clinical significance
has not been clarified and their molecular mechanisms
are complex [33]. In future sFasL may serve as an anti-
cancer therapeutic target, and it is important to block
sFasL to improve clinical outcome.
Our results showed a lack of correlation between
sFasL levels and patients survival. It is in line with
results by Shibakita et al. [32] who studied the expres-
sion of FasL in esophageal carcinomas.
In conclusion, the data presented in this paper
demonstrated that elevated serum soluble Fas ligand
were associated with advanced stage of disease and
poorly differentiated tumors of squamous cell
esophageal cancer.  
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